NYSE
$263.68▼ 0.17%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $634.73BShares out 24.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 3d agoAfter-hours26.10.22 05:1810-QEarnings#●●●
JOHNSON & JOHNSON
Johnson & Johnson (JNJ) has filed its 10-Q quarterly report for the period ending September 27, 2026, including certifications from its CEO and CFO regarding the company's financial condition and internal controls. This filing confirms that the financial statements fairly present the company's operational results in accordance with GAAP.…more
$263.68-0.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13Pre-market26.10.13 21:128-KKey event
JOHNSON & JOHNSON
Johnson & Johnson reported Q3 2026 sales of $25.399 billion and net earnings of $210 million. While net earnings declined 95.9% year-over-year due to talc litigation charges and acquisition costs, the company raised its 2026 full-year guidance to $101.2 billion in sales and $11.10 in adjusted EPS based on strong operational performance.…more
$263.68-0.17%vs prev closeView filingShare - 9.11Overnight26.09.11 09:514Ownership
JOHNSON & JOHNSON
Johnson & Johnson (JNJ) insider Daniel E. Pinto filed a Form 4 on September 10, 2026, reporting changes in beneficial ownership as of September 8, 2026. This filing serves as a standard disclosure of equity transactions by a corporate insider.…more
$263.68-0.17%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.22 20:47#●●●#●●●
Johnson & Johnson Reports 100% Procedural Success in Heart Rhythm Trials…more
Johnson & Johnson announced that its VARIPURE and Omny-IRE studies achieved 100% acute procedural success with a strong safety profile. The data highlights improved workflow efficiency and reduced ablation times for treating heart rhythm disorders.…more
$263.68-0.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 4d agoPre-market26.10.20 20:46
●●●●●●●● ●●●●● ●●●●●●
Johnson & Johnson has launched the Shockwave C2 Aero coronary catheter in the U.S., which reportedly cuts treatment time in half. This product launch is expected to strengthen the company's medical device portfolio and market competitiveness.…more
$263.68-0.17%vs prev closeShareBenzinga - 5d agoPre-market26.10.19 21:08
●●●●●●●● ●●●●● ●●●●●●
Johnson & Johnson reported that TREMFYA maintained or improved fistula remission in adults with Crohn's disease through 48 weeks in a Phase 3 study. These results further demonstrate the drug's efficacy in treating a challenging manifestation of the condition.…more
$263.68-0.17%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report